Tissue regeneration therapies through the use of autologous stem cell products is the firm’s focus. Aastrom’s platform manufacturing technology enables the production of patient-specific cell products with multiple tissue regenerative capabilities from a small sample of the patient's bone marrow.

Technology: Tissue Repair Cell (TRC) technology. The TRC-based products are comprised of a unique cell mixture containing stem and progenitor cell populations produced from a small amount of bone marrow taken from the patient.TRC-based products have been used in over 230 patients, and are currently in clinical trials for bone regeneration (long bone fractures and spine fusion) and vascular regeneration (critical limb ischemia) applications.

Products: Aastrom has reported positive interim clinical trial results for TRC-based cells. Clinical studies demonstrated safety and the ability of tissue repair cells to promote healing in bone regeneration. TRCs received Orphan Drug Designation from the FDA for use in the treatment of osteonecrosis of the femoral head. In addition, Aastrom is developing plans for TRC-based therapies to address cardiac and neural regeneration indications.

Development programs: Four in research, preclinical and clinical trials.

Bone regeneration  Phase 1/2 trials; Phase 2b planned in 2007
Critical limb ischemia Phase 1/2 trials; Phase 2b planned in 2007
Cardiac regeneration  in preclinical trials; Phase 1/2 planned for 2007
Neural regeneration  R&D; preclinical testing planned for 2007